A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...